

**etoricoxib 60mg, 90mg and 120mg tablets  
(Arcoxia<sup>o</sup>)**

**(No.313/06)**

**Merck Sharpe & Dohme Ltd**

**Product Update**

8 September 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**etoricoxib 60mg, 90mg and 120mg tablets (Arcoxia<sup>o</sup>)** are accepted for use in NHS Scotland for the symptomatic relief of osteoarthritis, rheumatoid arthritis and the pain and signs of inflammation associated with gouty arthritis, in patients for whom the use of etoricoxib is appropriate, taking account of current advice on the place in therapy of specific inhibitors of cyclo-oxygenase-2 (COX-2).

The new tablet formulation is smaller than the existing formulation at the same cost per dose.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 10 July 2006.*

**Chairman,  
Scottish Medicines Consortium**